Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease is a neurodegenerative disorder that causes age-dependent neurological and cognitive declines. The treatments for Alzheimer’s disease pose a significant challenge, because the mechanisms of disease are not being fully understood. Malfunction of the blood–brain barrier is increasingly recognized as a major contributor to the pathophysiology of Alzheimer’s disease, especially at the early stages of the disease. However, the underlying mechanisms remain poorly characterized, while few molecules can directly target and improve blood–brain barrier function in the context of Alzheimer’s disease. Here, we showed dysfunctional blood–brain barrier in patients with Alzheimer’s disease reflected by perivascular accumulation of blood-derived fibrinogen in the hippocampus and cortex, accompanied by decreased tight junction proteins Claudin-5 and glucose transporter Glut-1 in the brain endothelial cells. In the APPswe/PS1dE9 (APP/PS1) mouse model of Alzheimer’s disease, blood–brain barrier dysfunction started at 4 months of age and became severe at 9 months of age. In the cerebral microvessels of APP/PS1 mice and amyloid-β-treated brain endothelial cells, we found suppressed Wnt/β-catenin signalling triggered by an increase of GSK3β activation, but not an inhibition of the AKT pathway or switching to the Wnt/planar cell polarity pathway. Furthermore, using our newly developed optogenetic tool for controlled regulation of LRP6 (upstream regulator of the Wnt signalling) to activate Wnt/β-catenin pathway, blood–brain barrier malfunction was restored by preventing amyloid-β-induced brain endothelial cells impairments and promoting the barrier repair. In conclusion, targeting LRP6 in the Wnt/β-catenin pathway in the brain endothelium can alleviate blood–brain barrier malfunction induced by amyloid-β, which may be a potential treatment strategy for Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 2×
“These findings are consistent with the pathological changes in BECs in previous studies.(10,11,47,48)”
BackgroundResultAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452 · cited 1×
“1D), suggesting the BBB disruption and BEC dysfunction.(46) These findings are consistent with the pathological changes in BECs in previous studies.”
ResultBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · cited 2×
“8 This increase in permeability may result in increased levels of albumin, haemoglobin-derived peptides and prothrombin found in the perivascular brain tissues of patients with Alzheimer’s disease, 21–23 although some studies found no significant increase in the extravascular levels of fibrinogen,…”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853 · cited 2×
“The impairments of BBB structural components and BECs in particular, compromise the integrity and function of BBB.(16) Pathological changes in BECs are often reflect dysregulation of tight junctions,(17) including changes in expression of the tight junction protein Claudin-5,(18) and the tight junction-actin cytoskele…”
BackgroundWnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528 · cited 1×
“This signalling cascade involves canonical Wnt/β-catenin pathway, noncanonical Wnt/Ca pathway and Wnt/planar cell polarity (PCP) pathway.(27) Tight junction proteins and Glut-1 are the transcriptional targets of Wnt/β-catenin pathway in BECs,(26,28,29) while the integrity of endothelial tight junctions is regulated by…”
BackgroundAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · cited 2×
“Despite on-going efforts, the current understanding of Alzheimer’s disease pathophysiology 1–5 failed to guide to the development of drugs capable of arresting or reversing the disease progression.”
BackgroundWnt/β-catenin signaling controls development of the blood–brain barrier
Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C. J., Reis, M., Felici, A., Wolburg, H., Fruttiger, M., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806024 · Cited by 860
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 1×
“12, 61 62 By using both human Alzheimer’s disease specimens and APP BEC-related pathologies occur in the early stages of Alzheimer’s disease.”
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“These findings are consistent with the pathological changes in BECs in previous studies.(10,11,47,48)”
ResultBlood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation
Tornavaca, O., Chia, M., Dufton, N., Almagro, L. O., Conway, D. E., Randi, A. M., Schwartz, M. A., Matter, K., & Balda, M. S. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201404140 · Cited by 585 · cited 1×
“Pathological changes in BECs are often reflect dysregulation of tight junctions,(17) including changes in expression of the tight junction protein Claudin-5,(18) and the tight junction-actin cytoskeleton connecting protein zonula occludens-1 (Zo-1).(19) In a mouse model of Alzheimer’s disease, reduced expression of gl…”
BackgroundBlood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558 · cited 1×
“31,73 Curcumin, a natural compound, has been demonstrated to increase LRP6 levels to exert potential neuroprotective effects in several Alzheimer’s disease animal models 74–76 ; however, it is not suitable for Alzheimer’s disease treatment due to its low bioavailability.”
BackgroundFibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527 · cited 1×
“Nonetheless, leakage of blood protein fibrinogen into perivascular tissue following the breakdown of BBB is increasingly recognized as a contributor to neuropathology.(65) Deploying neuroprotectant to rescue behavioural deficits in Alzheimer’s disease model simultaneously improved BBB and cerebrovascular integrity, al…”
BackgroundKibar, Z., Vogan, K. J., Groulx, N., Justice, M. J., Underhill, D. A., & Gros, P. (2001) · Nature Genetics · doi:10.1038/90081 · Cited by 504 · cited 2×
“To better understand the mechanisms that impair BECs in Alzheimer’s disease, Wnt pathway was studied because of its involvement in BEC pathologies 26,28,29 and association with risk factors of Alzheimer’s disease, such as LRP6, GSK3 β , Dkk1 and Vangl2.”
BackgroundMicrovascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451
Shin, G., Gomez, A. M., Al-Hasani, R., Jeong, Y. R., Kim, J., Xie, Z., Banks, A., Lee, S. M., Han, S. Y., Yoo, C. J., et al. (2017) · Neuron · doi:10.1016/j.neuron.2016.12.031 · Cited by 396
Soluble Aβ oligomer production and toxicity
Larson, M. E., & Lesné, S. E. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07478.x · Cited by 356
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275 · cited 1×
“Despite ongoing efforts, the current understanding of Alzheimer’s disease pathophysiology failed to guide to the development of drugs capable of arresting or reversing the disease progression.(6,7)”
BackgroundLiu, C.-C., Tsai, C.-W., Deak, F., Rogers, J., Penuliar, M., Sung, Y. M., Maher, J. N., Fu, Y., Li, X., Xu, H., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.048 · Cited by 222 · cited 2×
“The Wnt signalling is significantly reduced in various cell types in the Alzheimer’s disease brains.(31,32) Which Wnt pathway is specifically involved in the BECs dysfunction in Alzheimer’s disease pathology remains, however, unknown.”
BackgroundClusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222 · cited 1×
“In addition, we found a significant decrease in Dkk1 in BECs in APP/PS1 mice, contrary to previously reported increases in Dkk1 in neurons, 32,69 with the underlying mechanism still unknown.”
ResultTomimoto, H., Akiguchi, I., Suenaga, T., Nishimura, M., Wakita, H., Nakamura, S., & Kimura, J. (1996) · Stroke · doi:10.1161/01.str.27.11.2069 · Cited by 204 · cited 1×
“in the perivascular brain tissues of patients with Alzheimer’s disease, although some studies found no significant increase in the extravascular levels of fibrinogen, prealbumin or immunoglobulins.(24,25) Wnt signalling is critical for the development of BECs.”
BackgroundLaksitorini, M. D., Yathindranath, V., Xiong, W., Hombach-Klonisch, S., & Miller, D. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-56075-w · Cited by 105
Merino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63
Cited by
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
The multifaceted role of WNT signaling in Alzheimer’s disease onset and age-related progression.
Kostes, W. W., & Brafman, D. A. (2023) · Cells · doi:10.3390/cells12081204 · Cited by 43
Intracerebral Nanoparticle Transport Facilitated by Alzheimer Pathology and Age
Tracy, G. C., Huang, K.-Y., Hong, Y.-T., Ding, S., Noblet, H. A., Lim, K. H., Kim, E. C., Chung, H. J., & Kong, H. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03222 · Cited by 24
Metadata
- Authors
- Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W., Zhang, K., Verkhratsky, A., Niu, J., & Yi, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-07-05
- Volume
- 145
- Issue
- 12
- Pages
- 4474-4488
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4283820481
- Cited by
- 210
- References
- 31
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.